Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
bioAffinity Technologies (Nasdaq: BIAF) will present research at CHEST 2025 (Oct 19-22) supporting the CyPath® Lung sample collection and transport methods used for its noninvasive lung cancer test.
Rossella Titone, PhD, will present the poster “The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests” on October 22, 2025 at 10:20 a.m. at poster board #4324. The company said the study validates protocols for home-collected sputum shipped to its lab, with physicians typically receiving results in two days. BioAffinity will be at Booth #2242 and highlighted recent case studies detecting Stage 1A lung cancers.
bioAffinity Technologies (Nasdaq: BIAF) received a notification of allowance from the USPTO for a patent titled “Detection of Early-Stage Lung Cancer in Sputum using Automated Flow Cytometry and Machine Learning.”
The allowed claim covers an AI-built algorithm and automated flow cytometry system that analyzes sputum cell populations and patient age to predict early-stage lung cancer and supports the company’s commercial CyPath® Lung test. The allowance expands bioAffinity’s global estate to 18 awarded and 33 pending patents across multiple jurisdictions.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW) announced it has regained compliance with Nasdaq continued listing requirements as of a letter dated October 14, 2025. Nasdaq confirmed the company meets Listing Rule 5550(a)(2) (minimum $1.00 closing bid) and Listing Rule 5550(b)(1) (minimum $2.5 million stockholders’ equity), allowing its common stock and warrants to continue trading on the Nasdaq Capital Market under BIAF and BIAFW.
Nasdaq also placed the company under a Mandatory Panel Monitor for one year; failure to comply with the Equity Rule during that period could lead to delisting, though the company can request a new hearing with the Nasdaq Listing Qualifications Hearing Panel before any delisting occurs.
bioAffinity Technologies (NASDAQ: BIAF) closed a registered direct offering of 720,000 shares at $2.50 per share on Oct 9, 2025, raising approximately $1.8 million. WallachBeth Capital acted as sole placement agent. The company said it will use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares were offered under a shelf registration on Form S-3 (File No. 333-275608) declared effective Nov 27, 2023. A prospectus supplement describing the offering terms will be filed with the SEC and made available on the SEC website when available.
bioAffinity Technologies (NASDAQ: BIAF) announced on October 9, 2025 that it closed a registered direct offering of 720,000 common shares at $2.50 per share, raising approximately $1.8 million before offering expenses. WallachBeth Capital acted as sole placement agent. The company said net proceeds will be used for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares were offered under a Form S-3 shelf registration declared effective November 27, 2023, and a prospectus supplement describing the offering terms will be filed with the SEC.
bioAffinity Technologies (NASDAQ: BIAF, BIAFW) entered definitive agreements for a registered direct offering of 720,000 common shares at $2.50 per share, expected to close on or about October 9, 2025. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales of CyPath® Lung, and for general corporate purposes. The shares are offered under an effective Form S-3 shelf registration (File No. 333-275608) and a prospectus supplement will be filed with the SEC.
bioAffinity Technologies (NASDAQ: BIAF) announced a registered direct offering of 720,000 shares of common stock at $2.50 per share, expected to close on or about October 9, 2025 subject to customary conditions. Gross proceeds are expected to be approximately $1.8 million before placement agent fees and offering expenses. WallachBeth Capital is sole placement agent. The company intends to use net proceeds for working capital, to support expected growing sales for CyPath® Lung, and for general corporate purposes. The shares are being offered under an effective Form S-3 shelf registration (File No. 333-275608); a prospectus supplement will be filed with the SEC.
bioAffinity Technologies (Nasdaq: BIAF) reported record CyPath® Lung test volumes in Q3 2025, with sales up 95% versus Q2 2025 and a 97% increase in sales for the first nine months of 2025 versus the same period in 2024. The company cited growing adoption by Veterans’ hospitals and expansion in the mid-Atlantic region.
Management highlighted a 77% increase in new patients using CyPath® Lung in Q3 and improved at-home sample collection compliance. Published case studies cited earlier detection (including Stage 1A) and fewer unnecessary invasive procedures.
bioAffinity Technologies (NASDAQ: BIAF) has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering consisted of 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 per pre-funded warrant).
WallachBeth Capital LLC served as the sole placement agent for the offering. The pre-funded warrants have an exercise price of $0.007 per share and will expire when exercised in full. The offering was conducted pursuant to an effective registration statement on Form S-1 filed with the SEC.
bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering included 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 for pre-funded warrants).
The pre-funded warrants have an exercise price of $0.007 per share and will expire upon full exercise. WallachBeth Capital, LLC served as the sole placement agent for this offering, which was conducted under an effective SEC registration statement on Form S-1.
["Raised $4.8 million in gross proceeds to strengthen balance sheet", "Successful completion of public offering indicates market interest"]